Investigational drug · Phase 2
BB-031
Also called: DTRI-031
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Acute Ischemic Stroke.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "BB-031"
First trial start
2024
Jul 31, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BB-031", any sponsor or status.
Conditions studied
As listed on its trial records.
- Acute Ischemic Stroke
Approved drugs for the same conditions: Stroke prevention · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "BB-031" as an intervention, largest first.
- Study of BB-031 in Acute Ischemic Stroke Patients (RAISE)Pivotal-lookingRecruiting
Basking Biosciences, Inc.Industry
NCT06226805 · 228 participants (planned) · Start Jul 31, 2024 · Primary completion Jun 2027
Drug: BB-031; Placebo · For: Acute Ischemic Stroke
Sites: Scottsdale, Arizona; Burlingame, California; Long Beach, California · 25 sites in all
Basking Biosciences, Inc.Industry
NCT07202663 · 72 participants · Start Nov 5, 2025 · Primary completion Mar 18, 2026
Drug: BB-025; BB-031 · For: Pharmacodynamics; Pharmacokinetics; Healthy Volunteers
Sites: Randwick, Australia
Newest research
PubMed records naming it or its code names, newest first.
- Von Willebrand factor A1 blockade prevents platelet-mediated sustained occlusion for the treatment of arterial thrombosis.
Mihalko EP, Kar R, Holthaus B, et al. · Commun Biol 2026
- Von Willebrand factor targeted thrombolysis in canine basilar artery occlusion.
Carfora A, Holthaus B, Yacoub S, et al. · Front Neurol 2024
- Dose-Dependent Von Willebrand Factor Inhibition by Aptamer BB-031 Correlates with Thrombolysis in a Microfluidic Model of Arterial Occlusion.
Shea SM, Thomas KA, Rassam RMG, et al. · Pharmaceuticals (Basel) 2022
- Preclinical Development of a vWF Aptamer to Limit Thrombosis and Engender Arterial Recanalization of Occluded Vessels.
Nimjee SM, Dornbos D, Pitoc GA, et al. · Mol Ther 2019
Also in development for Acute Ischemic Stroke
- TAK-755rADAMTS13, recombinant ADAMTS13Phase 33 trials
Takeda · Thrombotic Thrombocytopenic Purpura (TTP), Acute Ischemic Stroke
- SovateltideIRL-1620, PMZ-1620Phase 32 trials
Pharmazz, Inc. · Traumatic Brain Injury, Acute Ischemic Stroke, Cerebral Stroke
- JX10Phase 31 trial
Corxel Pharmaceuticals · Acute Ischemic Stroke
- SHPL-49Phase 31 trial
Shanghai Hutchison Pharmaceuticals Limited · Acute Ischemic Stroke
- LT3001Phase 23 trials
Lumosa Therapeutics Co., Ltd. · Acute Ischemic Stroke
- LT3001 DrugPhase 22 trials
Shanghai Pharmaceuticals Holding Co., Ltd · Acute Ischemic Stroke
- B2065Phase 21 trial
Tasly Pharmaceutical Group Co., Ltd · Acute Ischemic Stroke
- HRS-4029Phase 21 trial
Beijing Suncadia Pharmaceuticals Co., Ltd · Acute Ischemic Stroke
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.